Evaluation of new blue-blocking glasses for visual health
Visual Health Evaluation of New Designed Blue-blocking Glasses
This study is testing if new blue-blocking glasses can help reduce eye strain and improve vision for people who spend a lot of time on screens.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 23 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Beijing Tongren Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing/China) |
| Trial ID | NCT06984783 on ClinicalTrials.gov |
What this trial studies
This study evaluates the protective effects of a new type of blue-blocking glasses on visual fatigue caused by electronic display devices. Participants will wear either the new filtering glasses or regular glasses while performing tasks on visual display terminals (VDTs). Key outcome measures include visual fatigue scores, tear film break-up time, and other visual function indicators, which will be compared to baseline values. The goal is to determine if the new glasses can effectively reduce visual fatigue and improve overall visual function.
Who should consider this trial
Good fit: Ideal candidates are adults with mild refractive errors and good corrected visual acuity who do not have any significant eye conditions.
Not a fit: Patients with strabismus, amblyopia, or significant eye conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this could lead to improved visual comfort and reduced fatigue for individuals who frequently use electronic devices.
How similar studies have performed: While there is ongoing interest in blue-blocking glasses, this specific evaluation of a new design is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1. Adult population, regardless of gender 2. Refractive error is less than or equal to -2.5D and both eyes achieve corrected visual acuity of 0.8 or higher. 3. Normal intraocular pressure with no organic pathology. 4. No apparent symptoms of dry eye. 5. Willing to cooperate to complete all the tests. 6. Voluntarily signing the informed consent form. Exclusion Criteria: * 1: Individuals with strabismus and amblyopia exist. 2: Suffering from congenital eye conditions such as congenital cataracts or congenital retinal diseases. 3: Those who have undergone intraocular surgery (such as cataract removal, intraocular lens implantation, etc.). 4: Individuals with refractive media opacity (such as corneal lesions, lens opacity, etc.). 5: Abnormal intraocular pressure (IOP) (IOP \< 10 mmHg or IOP \> 21 mmHg, or a bilateral IOP difference of ≥5 mmHg). 6: Abnormal intraocular pressure (IOP) (IOP \< 10 mmHg or IOP \> 21 mmHg, or a bilateral IOP difference of ≥5 mmHg). 7: Only one eye meets the inclusion criteria. 8: Active corneal infections such as bacterial, fungal, viral, or other acute or chronic anterior segment inflammations. 9: Currently using medications that may lead to dry eye or affect vision and corneal curvature. 10: Other ocular conditions, such as dacryocystitis, eyelid disorders and abnormalities, abnormal intraocular pressure, and glaucoma. 11: Unable to undergo regular eye examinations.
Where this trial is running
Beijing, Beijing/China
- Beijing Tongren Hospitol,Capital Medical University — Beijing, Beijing/China, China (Recruiting)
Study contacts
- Study coordinator: cong wang
- Email: wangcong054@163.com
- Phone: 18788790178
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.